CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BrightGene Bio-Medical Technology Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BrightGene Bio-Medical Technology Co Ltd
Building C25-28, No.218 Xinghu Road, Sip
Phone: +86 51262620988p:+86 51262620988 SUZHOU, JNG  215123  China Ticker: 688166688166
Business Summary
BrightGene Bio-Medical Technology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of raw materials, pharmaceutical intermediates and preparations, as well as providing related technology transfer. The Company's products mainly cover therapeutic areas such as antiviral, antifungal, immunosuppression, respiratory system, anti-tumor and metabolism. Core products in the antiviral field include antifungal active pharmaceutical ingredients (APIs), Oseltamivir and others. The core products in the antifungal field include Caspofungin, Micafungin Sodium, Anidulafungin, Posaconazole. Core products in the immunosuppression field include Everolimus, Pimecrolimus and others. Core products in the respiratory system include Budesonide, Salmeterol, Fluticasone, and Tiotropium. Core products in the anti-tumor field include Eribulin and Lubitidin. Core products in the metabolic field include the Innovative drug BGM0504.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, General Manager JiandongYuan 53 1/1/2001 1/1/2001
Chief Financial Officer, Director YuanlaiZou 53 9/27/2024 8/24/2015
Deputy General Manager KaiLi 47 9/20/2021 1/1/2007
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 1,151 (As of 12/31/2024)
Outstanding Shares: 422,404,783 (As of 6/30/2025)
Shareholders: 12,604
Stock Exchange: SHA
Fax Number: +86 51262551799


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, September 9, 2025
Register now for our FAST Rating webinar on September 10 at 2:00 PM ET!